TP53 and myelodysplastic syndrome: On the contrary, its down-regulation with participation of a pivotal miRNA regulator, miR-595, induces p53 activation, apoptosis and inhibits proliferation, and in patients with myelodysplastic syndrome (MDS) with a miR-595 gene loss mutation, the risk of MDS is increased [19].